Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
01 2021
Historique:
received: 10 12 2019
revised: 01 09 2020
accepted: 12 09 2020
pubmed: 24 9 2020
medline: 24 4 2021
entrez: 23 9 2020
Statut: ppublish

Résumé

Optimal timing of surgery after neoadjuvant chemoradiotherapy (Nad-CRT) is still controversial in locally advanced rectal cancer (LARC). The primary goal of this study was to determine the best surgical interval (SI) to achieve the highest rate of pathological complete response (pCR) and secondly to evaluate the effect on survival outcomes according to the SI. Patients data were extracted from the international randomized trials: Accord12/0405, EORTC22921, FFCD9203, CAO/ARO/AIO-94, CAO-ARO-AIO-04, INTERACT and TROG01.04. Inclusion criteria were: age≥ 18, cT3-T4 and cN0-2, no clinical evidence of distant metastasis at diagnosis, Nad-CRT followed by surgery. Pearson's Chi-squared test with Yates' continuity correction for categorical variables, the Mann-Whitney test for continuous variables, Mann-Kendall test, Kaplan-Meier curves with log-rank test, univariate and multivariate logistic regression model was used for data analysis. 3085 patients met the inclusion criteria. Overall, the pCR rate was 14% at a median SI of 6 weeks (range 1-31). The cumulative pCR rate increased significantly when SI lengthened, with 95% of pCR events within 10 weeks from Nad-CRT. At univariate and multivariate logistic regression analysis, lengthening of SI (p< 0.01), radiotherapy dose (p< 0.01), and the addition of oxaliplatin to Nad-CRT (p< 0.01) had a favorable impact on pCR. Furthermore, lengthening of SI was not impact on local recurrences, distance metastases, and overall survival. This pooled analysis suggests that the best time to achieve pCR in LARC is at 10 weeks, considering that the lengthening of SI is not detrimental concerning survival outcomes.

Identifiants

pubmed: 32966845
pii: S0167-8140(20)30801-X
doi: 10.1016/j.radonc.2020.09.026
pii:
doi:

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

154-160

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Maria Antonietta Gambacorta (MA)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS - Roma, Italy; Istituto di Radiologia, Università Cattolica del Sacro Cuore - Roma, Italy.

Carlotta Masciocchi (C)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS - Roma, Italy.

Giuditta Chiloiro (G)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS - Roma, Italy; Istituto di Radiologia, Università Cattolica del Sacro Cuore - Roma, Italy. Electronic address: giuditta.chiloiro@policlinicogemelli.it.

Elisa Meldolesi (E)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS - Roma, Italy.

Gabriella Macchia (G)

Radiotherapy Unit, Gemelli Molise Hospital, Campobasso, Italy.

Johan van Soest (J)

Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University, Medical Centre+, The Netherlands.

Fenke Peters (F)

Department of Radiation Oncology, Leiden University Medical Center, The Netherlands.

Laurence Collette (L)

Department of Statistics, EORTC Headquarters, Brussels, Belgium.

Jean-Pierre Gérard (JP)

Department of Radiation Oncology, Centre Antoine Lacassagne, Nice Côte-d'Azur University, France.

Samuel Ngan (S)

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.

C Claus Rödel (CC)

Department of Radiotherapy and Oncology, University Hospital Frankfurt, Goethe University, Germany.

Andrea Damiani (A)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS - Roma, Italy.

Andre Dekker (A)

Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University, Medical Centre+, The Netherlands.

Vincenzo Valentini (V)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS - Roma, Italy; Istituto di Radiologia, Università Cattolica del Sacro Cuore - Roma, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH